---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-095905"
form_type: "8-K"
ticker: "PMN"
cik: "0001374339"
company_name: "ProMIS Neurosciences Inc."
filed_at: "2026-08-13T20:07:03+00:00"
generated_at: "2026-08-13T20:09:12.453749+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ProMIS Q2 net loss $11.7M; PRECISE-AD interim shows no ARIA-E, biomarker declines

## Summary
- Q2 2026 net loss $11.7M ($1.28/share) vs $10.1M ($7.26/share) in Q2 2025.
- Cash and short-term investments $53.4M at June 30, 2026, up from $6.1M at Dec 31, 2025; $70.1M net proceeds from Jan 2026 private placement.
- PRECISE-AD interim (136 patients): zero ARIA-E cases; 4.4% total ARIA (all mild ARIA-H); plasma pTau217 -15%, CSF MTBR-tau243 -13.3% in blinded pooled analysis.
- Expects unblinded 12-month topline data (cognitive outcomes) in Q1 2027; cash runway through 2027.
- Pipeline: PMN267 (TDP-43) and PMN442 (alpha-synuclein) advancing toward IND-enabling studies.

## SEC filing metadata
- accession: 0001104659-26-095905
- form_type: 8-K
- ticker: PMN
- cik: 0001374339
- company_name: ProMIS Neurosciences Inc.
- filed_at: 2026-08-13T20:07:03+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374339/000110465926095905/0001104659-26-095905-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374339/000110465926095905/pmn-20260813x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-095905
- JSON: https://secwatch.observer/filing/0001104659-26-095905.json
- Plain text: https://secwatch.observer/filing/0001104659-26-095905.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.